X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2939) 2939
Book Review (452) 452
Publication (217) 217
Newsletter (28) 28
Conference Proceeding (10) 10
Newspaper Article (9) 9
Book Chapter (7) 7
Magazine Article (6) 6
Book / eBook (1) 1
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2542) 2542
humans (1561) 1561
animals (1258) 1258
propylene glycols - therapeutic use (990) 990
male (906) 906
pharmacology & pharmacy (903) 903
sphingosine - analogs & derivatives (755) 755
fingolimod hydrochloride (746) 746
female (736) 736
rats (484) 484
immunosuppressive agents - therapeutic use (462) 462
mice (442) 442
propylene glycols - pharmacology (433) 433
sphingosine - therapeutic use (415) 415
adult (399) 399
propylene glycol (395) 395
propylene (302) 302
propylene-glycol (290) 290
fty720 (283) 283
middle aged (281) 281
clinical neurology (268) 268
propylene glycols - adverse effects (250) 250
propylene glycols - administration & dosage (247) 247
drug delivery systems (240) 240
analysis (233) 233
solubility (232) 232
phenylcarbamates (227) 227
sphingosine - pharmacology (225) 225
drugs (219) 219
abridged index medicus (210) 210
multiple sclerosis (204) 204
propylene glycols - chemistry (198) 198
in-vitro (193) 193
anticonvulsants - therapeutic use (190) 190
propylene glycol - chemistry (184) 184
administration, cutaneous (183) 183
propylene glycols (182) 182
chemistry, multidisciplinary (180) 180
immunology (180) 180
multiple sclerosis - drug therapy (171) 171
time factors (171) 171
transplantation (171) 171
treatment outcome (169) 169
dose-response relationship, drug (168) 168
permeability (167) 167
surgery (164) 164
immunosuppressive agents - pharmacology (160) 160
skin (159) 159
toxicology (159) 159
adolescent (154) 154
drug combinations (154) 154
disease models, animal (150) 150
aged (140) 140
in vitro techniques (140) 140
chemistry, pharmaceutical (138) 138
drug-delivery (138) 138
fingolimod (138) 138
vehicles (137) 137
child (136) 136
polyethylene glycols - chemistry (132) 132
administration, oral (129) 129
in-vivo (129) 129
epilepsy - drug therapy (128) 128
felbamate (128) 128
chemistry, medicinal (127) 127
rats, sprague-dawley (126) 126
toxicity (126) 126
skin - metabolism (125) 125
oral fingolimod (123) 123
nanoparticles (120) 120
skin absorption (120) 120
permeation (119) 119
pharmacokinetics (117) 117
multiple sclerosis, relapsing-remitting - drug therapy (114) 114
sphingosine 1-phosphate (114) 114
pharmacy (113) 113
propylene glycols - pharmacokinetics (113) 113
mice, inbred c57bl (111) 111
neurosciences (111) 111
article (110) 110
poly (109) 109
research (109) 109
polymers - chemistry (108) 108
health aspects (107) 107
pharmacology/toxicology (106) 106
drug therapy (104) 104
drug therapy, combination (104) 104
skin absorption - drug effects (102) 102
cancer (100) 100
biomedicine (99) 99
polymers (99) 99
immunosuppressive agents - administration & dosage (97) 97
rats, wistar (97) 97
sphingosine - administration & dosage (97) 97
delivery (96) 96
sphingosine (96) 96
immunosuppressive agents - adverse effects (95) 95
particle size (93) 93
administration, topical (92) 92
drug carriers - chemistry (92) 92
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2820) 2820
German (53) 53
French (32) 32
Japanese (19) 19
Italian (12) 12
Spanish (12) 12
Hungarian (8) 8
Russian (8) 8
Chinese (6) 6
Polish (6) 6
Finnish (3) 3
Portuguese (3) 3
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2010, Volume 362, Issue 5, pp. 402 - 415
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2010, Volume 362, Issue 5, pp. 387 - 401
In this 24-month, randomized trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod reduced the rates of relapse and disability... 
IMMUNE | SPHINGOSINE 1-PHOSPHATE RECEPTORS | MEDICINE, GENERAL & INTERNAL | FTY720 | CENTRAL-NERVOUS-SYSTEM | PHASE-II EXTENSION | AGONISTS | Arrhythmias, Cardiac - chemically induced | Herpesviridae Infections - etiology | Sphingosine - adverse effects | Herpesviridae Infections - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Young Adult | Propylene Glycols - adverse effects | Sphingosine - administration & dosage | Propylene Glycols - therapeutic use | Adult | Female | Immunosuppressive Agents - administration & dosage | Disability Evaluation | Liver Function Tests | Multiple Sclerosis, Relapsing-Remitting - pathology | Macular Edema - chemically induced | Double-Blind Method | Administration, Oral | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Kaplan-Meier Estimate | Fingolimod Hydrochloride | Disease Progression | Magnetic Resonance Imaging | Sphingosine - analogs & derivatives | Propylene Glycols - administration & dosage | Adolescent | Brain - pathology | Immunosuppressive Agents - adverse effects | Sphingosine - therapeutic use | Multiple sclerosis | Usage | Magnetic resonance imaging | Placebos | Dosage and administration | Diagnosis | Drug therapy | Comparative analysis | Immunosuppressive agents | Interferon | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article
JAMA Neurology, ISSN 2168-6149, 04/2015, Volume 72, Issue 4, pp. 405 - 413
Journal Article
Nature, ISSN 0028-0836, 2013, Volume 502, Issue 7471, pp. 327 - 332
Progressive phases of multiple sclerosis are associated with inhibited differentiation of the progenitor cell population that generates the mature... 
OLIGODENDROCYTE DIFFERENTIATION | PROGENITOR CELLS | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | MUSCARINIC RECEPTOR SUBTYPES | THYROID-HORMONE | MYELIN REPAIR | MULTIDISCIPLINARY SCIENCES | EMBRYONIC STEM-CELLS | SPINAL-CORD | CENTRAL-NERVOUS-SYSTEM | PRECURSOR CELLS | Cuprizone - therapeutic use | Oligodendroglia - metabolism | Optic Nerve - cytology | Recurrence | Antiparkinson Agents - pharmacology | Coculture Techniques | Myelin Sheath - drug effects | Receptor, Muscarinic M1 - antagonists & inhibitors | Stem Cells - cytology | Myelin Proteolipid Protein - pharmacology | Myelin Sheath - metabolism | Antiparkinson Agents - therapeutic use | Oligodendroglia - drug effects | Cuprizone - pharmacology | Encephalomyelitis, Autoimmune, Experimental - chemically induced | Propylene Glycols - therapeutic use | Immune System - immunology | Female | Oligodendroglia - cytology | Benztropine - therapeutic use | Propylene Glycols - pharmacology | Encephalomyelitis, Autoimmune, Experimental - pathology | Myelin Sheath - pathology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Mice, Inbred C57BL | Receptor, Muscarinic M3 - metabolism | Fingolimod Hydrochloride | Rats | Receptor, Muscarinic M3 - antagonists & inhibitors | Oligodendroglia - pathology | Sphingosine - pharmacology | Regeneration - drug effects | Sphingosine - analogs & derivatives | Animals | Cell Differentiation - drug effects | Models, Biological | Immune System - drug effects | Multiple Sclerosis - pathology | Stem Cells - drug effects | Sphingosine - therapeutic use | Mice | Benztropine - pharmacology | Receptor, Muscarinic M1 - metabolism | Multiple Sclerosis - drug therapy | Benztropine | Multiple sclerosis | Myelination | Physiological aspects | Oligodendroglia | Dosage and administration | Drug therapy | Cell differentiation | Cell culture | Dopamine | Drug dosages | Rodents | Cell cycle | Index Medicus
Journal Article
Journal Article